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Introduction
Relapsed and refractory acute myeloid leukemia (AML) is 
a highly aggressive and resistant disease that is associated 
with poor response to standard therapy and with poor 
prognosis [1]. Therefore, there is an urgent need for new 
therapies for this disease, especially in elderly patients with 
limited tolerance of aggressive induction therapy.
In our previous studies, we showed that in comparison 
with normal hematopoietic cells, AML cells have increased 
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Abstract
Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and 
signaling demands of the cell by increasing mitochondrial biogenesis and 
 mitochondrial protein translation. Blocking mitochondrial protein synthesis 
through genetic and chemical approaches kills human AML cells at all stages 
of development in vitro and in vivo. Tigecycline is an antimicrobial that we 
found inhibits mitochondrial protein synthesis in AML cells. Therefore, we 
conducted a phase 1 dose- escalation study of tigecycline administered intrave-
nously daily 5 of 7 days for 2 weeks to patients with AML. A total of 27 adult 
patients with relapsed and refractory AML were enrolled in this study with 42 
cycles being administered over seven dose levels (50–350 mg/day). Two patients 
experienced DLTs related to tigecycline at the 350 mg/day level resulting in a 
maximal tolerated dose of tigecycline of 300 mg as a once daily infusion. Phar-
macokinetic experiments showed that tigecycline had a markedly shorter half- life 
in these patients than reported for noncancer patients. No significant pharma-
codynamic changes or clinical responses were observed. Thus, we have defined 
the safety of once daily tigecycline in patients with refractory AML. Future 
studies should focus on schedules of the drug that permit more sustained target 
inhibition.
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reliance on oxidative metabolism, reflecting the higher 
energy, metabolic and signaling demands of the cell as 
well as reduced spare reserve capacity in the respiratory 
chain [2–5]. AML cells meet these higher demands by 
increasing mitochondrial protein translation carried out 
by mitochondrial ribosomes in the mitochondrial matrix. 
Mitochondrial ribosomes differ from eukaryotic cytosolic 
ribosomes in their structure and chemical properties [6]. 
One key difference is that mitochondrial ribosomes use 
unique protein translation machinery with distinct initia-
tion and elongation factors.
Mitochondrial elongation factor Tu (EF- Tu) brings 
aminoacyl- tRNAs in complex with GTP to the decoding 
site on the mitochondrial ribosome [7]. Previously, we 
showed that an shRNA- mediated knockdown of EF- Tu 
reduced the growth and viability of AML cell lines [2]. 
In addition, the knockdown of EF- Tu decreased levels of 
Cox- 1 and Cox- 2 that are subunits of respiratory complex 
IV in the electron transport chain in mitochondria and 
are translated by mitochondrial ribosomes. However, knock 
down of EF- Tu did not alter the levels of Cox- 4 that is 
a component of the same respiratory complex but is 
encoded by the nuclear genome and translated by cyto-
plasmic ribosomes [2, 8].
Through a chemical screen, we discovered that tigecy-
cline kills human AML differentiated blasts as well as 
leukemic stem cells in vitro and in vivo by blocking 
mitochondrial protein synthesis [2]. Tigecycline is a struc-
tural analog of tetracycline, and is mostly used as a broad- 
spectrum antibiotic against gram- positive and 
gram- negative pathogens [9–11]. Currently, it is approved 
for the treatment of adults with complicated intraabdomi-
nal, skin, soft tissue and skin structure infections, and 
community- acquired bacterial pneumonia [9, 12]. As an 
antimicrobial, tigecycline reversibly binds to the 30S subunit 
of the bacterial ribosome, blocking the aminoacyl- tRNA 
from entering the A site, thereby inhibiting elongation 
of the peptide chain and protein synthesis in bacteria 
[13]. Consistent with its design as a more potent ribo-
somal inhibitor than minocycline or tetracycline, tigecycline 
inhibits bacterial protein synthesis 3- and 20- fold greater 
than minocycline and tetracycline, respectively [14, 15].
In AML cells, tigecycline inhibits cell growth by impair-
ing mitochondrial protein synthesis. Similar to EF- Tu 
knockdown, tigecycline decreased levels of Cox- 1 and 
Cox- 2, but not nuclear- encoded Cox- 4, leading to reduced 
respiratory chain activity and oxygen consumption. 
Tigecycline killed AML blast cells and leukemic stem cells 
with increased mitochondrial mass and greater reliance 
on oxidative phosphorylation, but was not cytotoxic to 
normal hematopoietic cells or stem cells [2, 16]. Therefore, 
due to the preclinical efficacy of tigecycline in AML cells 
as well as its safety as an antimicrobial, we carried out 
a phase I dose- escalation study of intravenous tigecycline 
in patients with relapsed and refractory AML.
Methods
Patient eligibility
Patients at least 18 years of age with relapsed or refrac-
tory AML were eligible to participate in this study. Eligible 
patients included those with no other potentially curative 
or standard salvage therapy options, or without prior 
treatment who are not eligible for induction chemotherapy 
as defined by age ≥80 or age >70 with poor risk cytoge-
netics (3 or more abnormalities, - 5/del(5q), 3q abnormali-
ties, or - 7), or stable comorbidities that would preclude 
induction chemotherapy such as left ventricular ejection 
fraction (LVEF) <40% and/or diffusing capacity of the 
lungs for carbon monoxide (DLCO) <60% expected.
Patients were required to have an Eastern Cooperative 
Oncology Group (ECOG) performance status of ≤2 and 
normal liver and kidney function (total serum bilirubin 
<1.5 times, serum creatinine <2 times, aspartate 
 aminotransferase and alanine aminotransferase <2 times 
the upper limit of normal [ULN]). In addition, study 
entry required recovery (≤ grade 1) from nonhematologic 
toxicity from prior chemotherapy, and patients were 
required to provide informed written consent and comply 
with the study procedures to be eligible.
Patients were excluded from the study if they were 
allergic to tetracycline or minocycline, received tigecycline 
in the last month prior to registration, or at any point 
as an anticancer agent. In addition, patients receiving 
chemotherapy, other than hydroxyurea, to control circu-
lating blast counts or receiving concomitant therapy with 
linezolid or chloramphenicol, compounds that are known 
to inhibit mitochondrial protein synthesis, were not eli-
gible. Patients with uncontrolled medical illnesses, infec-
tions or psychiatric conditions, were excluded from the 
study. Patients using any other investigational antileukemic 
therapy within 14 days of registration of the study were 
ineligible. Women who were pregnant or breastfeeding 
were not considered for this study.
Study drug
Tigecycline was purchased from the local pharmacy of 
each institution as a sterile, lyophilized orange powder 
or cake. Each glass vial contained 50 mg of tigecycline 
for intravenous use. Each vial was reconstituted as per 
the manufacturer’s instructions (Pfizer, NY, NY) with 
5.3 mL of 5% dextrose, 0.9% sodium chloride, or lactated 
Ringer’s injection and swirled to dissolve the drug yielding 
a yellow to orange solution containing tigecycline at a 
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concentration of 10 mg/mL. Before administration, recon-
stituted tigecycline was diluted by immediately withdrawing 
the drug from the vial and adding it to 500 mL of 0.9% 
sodium chloride. The maximum infusion concentration 
was 1 mg/mL.
Prior to reconstitution, tigecycline was stored at 20 to 
25°C. Once reconstituted, tigecycline was allowed to be 
stored at room temperature for up to 24 h (up to 6 h 
in the vial and the remaining time in the intravenous 
bag). Alternatively, reconstituted tigecycline was stored 
refrigerated at 2–8°C for up to 48 h following immediate 
transfer of the reconstituted solution into the intravenous 
bag. The drug was infused over 1 h ± 10 min. Since 
tigecycline has a reported t1/2 of 27–43 h and was stable 
for only 6 h at room temperature in the vial, this pre-
vented continuous infusion and once daily dose of 
 tigecycline was selected for this study.
To prevent nausea and vomiting associated with tige-
cycline, patients were instructed to consume a meal 2 h 
prior to drug administration. In addition, patients received 
granisetron (2 mg orally or 1 mg intravenously) or a 
suitable alternative 30 min prior to tigecycline administra-
tion. Additional antiemetics were given at the discretion 
of the treating physician. Of note, consumption of food 
does not affect the tigecycline concentration in the serum 
[17].
The investigational new drug (IND) application for 
tigecycline was held by University Health Network and 
obtained using the product insert of tigecycline that pro-
vided information on drug safety, pharmacokinetics, and 
metabolism.
Trial design
This was a phase I open- label, multicenter, 3+3 dose- 
escalation study of tigecycline in patients with AML. One 
cycle of treatment was defined as 3 weeks, of which tige-
cycline was administered intravenously daily for 5 of 7 days 
(Monday–Friday) for 2 weeks followed by a rest period 
of 1 week. Patients continued with treatment cycles until 
disease progression. Three patients were enrolled and 
treated at each dose level in sequential cohorts according 
to the schedule in Table 1. The cohort was expanded if 
1 of the 3 patients experienced a dose- limiting toxicity 
(DLT). In that case, three more patients were enrolled 
with the same dose. If none of these three additional 
patients experienced a DLT in cycle 1, dose escalation 
was allowed.
Additional patients could be enrolled at any dose level 
as the trial was conducted at multiple sites and multiple 
patients could have been offered the trial simultaneously 
as enrollment was competitive. Patients were enrolled and 
started on therapy prior to the previous patient 
completing the full course of therapy. All adverse events 
were rapidly reported to closely oversee the progress of 
all patients on study and detect important adverse events 
that may have required modifying or stopping the study.
A DLT was defined as any grade 3, 4, or 5 adverse 
event attributable to study drug (definitely, probably, or 
possibly) during the first cycle of treatment. At the inves-
tigator’s discretion, grade 3 nausea, or grade 3 or 4 vom-
iting, if manageable with supportive care measures, was 
not considered a DLT. Dose escalation was permitted if 
no DLTs were observed in the first three patients or no 
more than 1 DLT among six patients were encountered 
in the first cycle.
The maximally tolerated dose (MTD) was defined as 
the next lower dose below the one where DLTs preclud-
ing dose escalation were observed. If the MTD was not 
reached by dose level seven, no further dose escalation 
was allowed. Patients were withdrawn from treatment in 
the event of grade 3 or 4 toxicity occurring during cycle 
1 of treatment. If grade 3 or 4 toxicity occurred after 
cycle 1 of treatment, therapy with tigecycline was stopped 
until toxicity was resolved to grade 1 or less, and the 
treatment reduced by one dose level.
Endpoints and assessment
Patients that progressed during or after completing the 
3- week treatment cycle were withdrawn from the study. 
Patients that did not progress and did not have evidence 
of significant toxicity were eligible to receive additional 
cycles of tigecycline. The following response criteria was 
used: Complete response (CR): <5% blasts in a normocel-
lular bone marrow, absolute neutrophil count (ANC) 
>1.0 × 109/L and platelets >100 × 109/L, and no extramed-
ullary disease; Complete response, incomplete platelet 
recovery (CRp): meets the criteria for CR except platelets 
<100 × 109/L, but independent of platelet transfusions; 
partial response (PR): at least 50% reduction in bone 
marrow blasts with 5–15% residual marrow blasts, ANC 
Table 1. Tigecycline dose escalation schedule.
Dose level Administered dose (mg) n
1 50 3
2 100 3
3 150 3
4 200 5
5 250 4
6 300 4
7 350 51
Total 27
1One patient received cycle 1 at 350 mg/m2 and cycles 2 and 3 at 
300 mg/m2.
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>1.0 × 109/L and platelets >50 × 109/L, independent of 
transfusions; morphologic leukemia- free state (MLF): <5% 
blasts in an assessable sample with at least 200 nucleated 
cells counted without neutrophils and platelet recovery; 
and no response (NR): does not meet the criteria for 
CR, CRp, PR, or morphologic leukemia- free state.
Pharmacokinetics
Five mL of peripheral blood samples were acquired from 
patients enrolled in the study in heparinized tubes on 
screening day, at 1 h prior to infusion, at the end of 
infusion (0 h), and at 0.5, 1, 2, 4, and 24 h after the 
end of infusion. It should be noted that no end of infu-
sion samples were acquired for the three patients at the 
50 mg dose. Additional samples were acquired prior to 
infusion on days 3, 4, 5, and 12. Within an hour post-
collection, blood samples were centrifuged at 1500g for 
10 min at 4°C to collect plasma layer, which was frozen 
until analysis. Plasma concentrations of tigecycline were 
determined using a fully validated LC- MS/MS method, 
and resulting values were used for noncompartmental 
analysis. Observed Cmax, areas under the curve (AUC) 
from 0–24 h is calculated using linear trapezoidal extrapo-
lation, and t1/2 are reported.
Pharmacodynamics
Peripheral blood (20 mL) was obtained pretreatment and 
during the cycle one on patients with circulating blasts. 
Mononuclear cells were isolated by Ficoll–Hypaque sepa-
ration and depleted of CD3+, CD19+ and glycophorin A+ 
cells using one round of EasySep™ negative selection 
(StemCell Technologies, Catalog no.: 19309). Negative 
selection was omitted for patients 8, 11, 13, 19, 21, 23, 
and 24 due to low mononuclear cell count after Ficoll–
Hypaque separation. Negative selection was performed 
according to manufacturer’s protocol. Briefly, mononuclear 
cells (5 × 107 cells/mL) were suspended in phosphate 
buffer saline (PBS) with 2% fetal bovine serum (FBS) 
and 1 mmol/L ethylenediaminetetraacetic acid (EDTA) 
and incubated with negative selection cocktail at room 
temperature for 10 min. Magnetic nanoparticles were added 
to the mix and the suspension incubated at room tem-
perature for 10 min followed by separation.
120 μL of nDBM lysis buffer (n dodecyl beta maltoside 
(Sigma, Catalog no.: D4641) made in PBS with protease 
inhibitors was added to 5 × 106 cells and incubated on 
ice for 30 min with periodic vortexing. Samples were 
centrifuged at 15,800 × g for 20 min at 4°C, and the 
protein concentration of the cell lysate was measured, 
using the DC protein assay. Samples were not boiled after 
the addition of loading buffer to avoid protein 
precipitation [2, 18] and 20 μg of protein was loaded 
per lane for gel electrophoresis. Levels of Cox- 1 and Cox- 4 
protein were analyzed using immunoblotting. Anti- Cox- 1 
antibody (Santa Cruz Biotechnology Inc., Catalog no.: 
sc- 58347) and anti- Cox- 4 antibody (Molecular Probes, 
Catalog no.: A21347) were used at 1:1000 and 1:5000 
dilution, respectively, and incubated overnight at 4°C. 
Secondary antimouse HRP (GE Healthcare Life Sciences, 
catalog no.: NA931V) antibody was used at 1:1000 dilu-
tion and incubated for 1 h at room temperature. 
Quantitative densitometry was performed on the western 
blots to calculate the ratio of Cox- 1:Cox- 4 on different 
days. Samples from the following patients were excluded 
from the analysis due to lack of sufficient protein for 
immunoblotting (patient 3, 5, 6, 8, 13, 14, 17, and 19) 
or technical challenges with the assay (patients 4 and 9).
1x107 mononuclear cells were used to isolate mRNA 
using the RNeasy mini kit (Qiagen, Catalog no.: 74134). 
Isolated mRNA was stored at −80°C and transferred to 
a facility for NanoString analysis. Cox- 1 mRNA was 
 analyzed using the NanoString protocol (NanoString 
Technologies Inc.). Samples from patients 21, 23, 24, 25, 
and 27 were not analyzed for mRNA due to lack of sample 
amount.
Statistical analysis
Statistical analyses were primarily descriptive in nature 
and a summary of statistics was carried out for all safety 
and efficacy parameters by dose group. For continuous 
variables, data was presented using number, mean, and 
median; standard deviation; and minimum and maximum. 
For categorical variables, summary tabulations of the counts 
and percentages in each parameter were presented.
Results
Demographics
The demographics of the patients enrolled in the study 
are outlined in Table 2. Twenty- seven patients with AML 
were enrolled in the study from June 2011 to July 2014; 
all patients received tigecycline and were included in the 
analysis. The median age of patients was 70 years (range 
44–84 years) and 59% were male. One patient (4%) had 
good- risk cytogenetics, 12 patients (44%) had intermediate- 
risk cytogenetics, seven patients (26%) had poor- risk 
cytogenetics, and the karyotype was unknown in seven 
patients (26%) using previously established criteria for 
cytogenetic risk [19]. Patients had a median of two prior 
therapies (range 0–8). A total of 42 cycles were admin-
istered over seven dose levels of which 30 were completed 
(71%) by 22 patients. A summary of the number of study 
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cycles per patient at different dose levels is shown in 
Table 3. Ten patients received more than one cycle and 
one patient received four cycles of study drug.
Safety
No grade 3 or 4 toxicity related to study drug was observed 
up to 300 mg/day, the first six dose levels. Two patients 
experienced DLTs related to tigecycline at the 350 mg/
day level (7th dose level). On the last day of cycle 1 at 
the 350 mg/day dose level, a 75- year- old female experi-
enced an asymptomatic and reversible grade 3 elevated 
aspartate aminotransferase and grade 3 congestive heart 
failure that were judged to be related to tigecycline 
treatment. Prior to starting the study, this patient had 
risk factors for cardiomyopathy, fluid retention and mild 
edema of the legs. By MUGA scan, the ejection fraction 
was 57% prior to the study and decreased to 30% at the 
time of the DLT. The levels of aspartate aminotransferase 
decreased toward normal within a week after the patient 
was taken off tigecycline, but the heart failure remained 
unchanged until her death from progressive disease a 
month later.
Another patient in this dose cohort, a 78- year- old female, 
tolerated tigecycline well for the first 5 days, but developed 
an asymptomatic grade 3 increase in serum amylase and 
a grade 3 increase in lipase on day 8 that were possibly 
related to tigecycline. The drug was stopped and the 
abnormal enzyme levels returned to normal after 10 days 
off study drug. No other causes for pancreatitis, such as 
gall stones, were identified.
In addition, two patients in the 200 mg/day dose 
cohort were taken off treatment due to grade 3 or 4 
AEs, which were judged to be unrelated to tigecycline 
treatment. A 70- year- old male experienced grade 3 
hyperbilirubinemia after 5 days of treatment in cycle 1 
and an 84- year- old male experienced grade 3 atrial fibril-
lation on day 9 of treatment in cycle 1. Also on day 
10 of cycle 1, a 77- year- old male in the 350 mg/day 
cohort experienced a grade 3 elevated aspartate ami-
notransferase that was judged to be unrelated to tige-
cycline treatment. The patient was taken off treatment 
to resolve the elevated liver enzymes. Furthermore, a 
69- year- old male in the 150 mg/day dose cohort died 
of grade 4 septic shock and neutropenic fever after 
completing cycle 1. The death was judged to be unre-
lated to tigecycline treatment.
The other AEs greater than grade 1 that were pos-
sibly related to tigecycline treatment were nausea, diar-
rhea, and elevated lactate dehydrogenase levels in two 
patients each, and elevated bilirubin levels, hypoalbu-
minemia, fatigue, vomiting, and anorexia in one patient 
each (Table 4). These AEs developed in patients at 
dose levels of 150 mg/day tigecycline and higher, while 
no AEs developed at the first two dose levels of 50 
and 100 mg/day tigecycline. Thus, the MTD of tige-
cycline when given as a once daily 1 h infusion in this 
study was 300 mg/day.
Disease response
None of the patients had evidence of disease response. 
The treatment was terminated because patients had pro-
gressive disease or no response (18 patients, 67%), grade 
3 or 4 AEs (three patients, 11%), AEs unrelated to tige-
cycline (two patients, 7%), withdrawn from treatment 
(three patients, 11%), or died (one patient, 4%).
Table 2. Demographics and baseline characteristics of patients enrolled 
in the study.
n
n 27
Age Median (range), years 70 (44–84)
Male 16
Diagnosis
Relapsed AML 15
Refractory AML 10
AML; not eligible for chemotherapy 2
Cytogenetic Risk Group 
Good 1
Intermediate 12
Poor 7
Unknown 7
Prior therapies Median (range) 2 (0–8)
IC: Induction Chemotherapy 24
PC: Postremission Chemotherapy 8
HSCT: Hematopoietic Stem Cell Transplantation 2
Other 4
Total cycles administered 42
Total cycles completed 30
AML, Acute myeloid leukemia.
Table 3. Study drug exposure in patients treated with tigecycline.
Dose 
(mg)
Total cycles per patient1, n (%)
1 2 3 4
50 1 (33) 2 (67)
100 3 (100)
150 2 (67) 1 (33)
200 3 (60) 1 (20) 1 (20)
250 2 (50) 1 (25) 1 (25)
300 3 (75) 1 (25)
350 3 (60) 1 (20) 1 (20)2
Total 17 (63) 6 (22) 3 (11) 1 (4)
1Cycles not completed have also been counted.
2Cycle 1 at 350 mg/m2 and cycles 2 and 3 at 300 mg/m2.
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Pharmacokinetics
Pharmacokinetic data was obtained from all 27 patients 
and Tmax was observed at the end of infusion. Since 
samples were not acquired until 30 min past the end of 
infusion for the three patients at the 50 mg dose level, 
the observed Cmax values are below the true Cmax at that 
dose. As shown in Figure 1A and B, Cmax and AUC 
increased as a function of dose and appeared linear 
throughout the 0–350 mg dose range.
Semilogarithmic plots of plasma concentration versus 
time exhibited a constant slope between 2 and 24 h, 
supporting the determination of an apparent half- life 
(t1/2). The apparent t1/2 of tigecycline appeared to increase 
slightly as a function of dose, and had a mean value 
of 9.5 ± 1.9 h and a range of 6.0–14.6 h over the dose 
range (Fig. 1C). This half- life is shorter than published 
half- lives for tigecycline that range from 27 to 43 h [17, 
20]. Based on the published half- life values of tigecycline, 
steady- state should not have been achieved until at least 
day 5, and based on the ratio of half- life to dosing 
interval that steady- state trough concentration should 
have increased markedly following these daily infusions. 
Instead, consistent with the relatively short t1/2 deter-
mined in this study, the measured predose tigecycline 
concentrations on days 2–12 did not show a significant 
or consistent increase above the day two values (Figure 
S1). The apparent increase in predose concentration seen 
Table 4. Summary of adverse events related to tigecycline by dose level 
and grade based on events.
Dose 
(mg)
Adverse event All 
grade
Grade 
≥3
50 None observed
100 Nausea 1 0
150 Hypomagnesemia 1 0
LDH elevated 1 0
Nausea 3 0
Photosensitivity 1 0
Vomiting 1 0
200 Blood bilirubin increased 1 0
Diarrhea 1 0
Fatigue 1 0
Gastroesophageal reflex disease 1 0
LDH elevated 1 0
Nausea 3 0
Pruritus 1 0
250 Diarrhea 2 0
Fatigue 1 0
Nausea 1 0
Vomiting 2 0
300 Anorexia 1 0
Diarrhea 1 0
Hypomagnesemia 2 0
Nausea 2 0
Vomiting 1 0
350 Alanine aminotransferase elevated 1 0
Alkaline phosphatase elevated 1 0
Aspartate aminotransferase elevated 1 1
Diaphoresis 1 0
Diarrhea 1 0
Heart failure 1 1
Hot flashes 1 0
Hypoalbuminemia 1 0
Lipase elevated 1 1
Nausea 3 0
Serum amylase elevated 1 1
Vomiting 1 0
Weight gain 2 0
Figure 1. Plasma levels of tigecycline are proportional to the 
administered dose. (A) The peak plasma concentrations (Cmax), (B) areas 
under the curve (AUC) through 0–24 h, and (C) half- life following 
administration of tigecycline. Peripheral blood samples were collected at 
predose (−1 h), and 0, 0.5, 1, 2, 4, and 24 h postdose. End of infusion 
samples were not acquired for the patients at the 50 mg dose. 
Additional predose samples were collected on days 3, 4, 5, and 12. 
Plasma concentrations of tigecycline were determined using a fully- 
validated LC- MS/MS method, and resulting values were used for 
noncompartmental analysis. Data are presented as mean ± SEM.
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on day 4 for the 350 mg dose cohort is skewed by a 
very high measured value for one patient, and that 
increased predose concentration is neither maintained 
nor increased further on subsequent days. This supports 
our conclusion that the predose concentration at day 
four is an outlier, and not indicative of true accumula-
tion of drug.
Pharmacodynamics
We previously showed that tigecycline inhibits mito-
chondrial protein synthesis in AML cells resulting in 
a reduction in mitochondrially encoded proteins such 
as Cox- 1 but no change in nuclear encoded proteins 
such Cox- 4 that are both components of respiratory 
chain complex IV [2, 8]. Along with the reduction in 
mitochondrially encoded proteins, we observed a con-
comitant and compensatory upregulation of mRNA 
encoding the mitochondrial proteins. Peripheral blood 
was obtained from all 27 patients pre and posttreat-
ment with tigecycline. Mononuclear cells were isolated 
and changes in mRNA and mitochondrial proteins were 
measured by NanoString RNA analysis and immuno-
blotting, respectively. Adequate material was available 
for mRNA analysis from 20 patients and for protein 
analysis from 17 patients. Consistent with the lack of 
clinical response and short half- life of the drug, no 
significant pharmacodynamics changes were observed. 
We observed greater than a 1.3- fold increase in the 
level of Cox- 1 mRNA compared to pretreatment levels 
in seven patients (patient 1 and 2 = 50 mg, patient 
8 and 9 = 150 mg, patient 18 = 250 mg, patient 
20 = 300 mg, and patient 22 = 350 mg) (Fig. 2A). 
Four patients had more than a twofold reduction in 
protein levels of Cox- 1 relative to Cox- 4 after treat-
ment with tigecycline (patient 11 = 200 mg, patient 
15 = 250 mg, patient 27 = 300 mg, and patient 
24 = 350 mg) (Fig. 2B). However, there was no cor-
relation between patients with increased Cox- 1 mRNA 
and decreased Cox- 1 protein levels.
Discussion
We previously showed that mitochondrial biogenesis and 
energetics are dysregulated in AML cells, and pharmaco-
logically targeting the mitochondrial protein translation 
is a novel antileukemic strategy [2, 5, 21]. We identified 
tigecycline, an antimicrobial agent, from a chemical screen 
with anticancer activity in preclinical studies of AML [2]. 
Tigecycline was preferentially cytotoxic to AML cells and 
leukemic stem and progenitor cells, compared to normal 
hematopoietic cells in vitro and in vivo [2]. Motivated 
by these results, we conducted a phase I study of 
Figure 2. Pharmacodynamic changes in mitochondrial proteins after 
treatment with tigecycline. Leukemic blasts from peripheral blood samples 
were obtained on screening day, predose and on days 4, 8 and 11/12 
postdose (−1 h) after tigecycline treatment. Mononuclear cells were isolated, 
using Ficoll–Hypaque separation followed by EasySep™ negative selection, 
other than samples from patients 8, 11, 13, 19, 21, 23, and 24 for which 
negative selection step was omitted. (A) Cox- 1 and β2M were measured by 
NanoString protocol in mononuclear cells from patients before and after 
treatment with tigecycline. Samples before tigecycline treatment were 
predose from day 1 or screening day samples for patients 6 and 14. Samples 
after tigecycline treatment were from day 11/12 (or on day 8 for patients 8, 
15, 17, 22 and 26 or on day 5 for patient 13). Patients 10, 12, and 20 were 
excluded due to missing pretreatment samples, and mRNA analysis was not 
carried out for patients 21, 23, 24, 25 and 27. Cox- 1 RNA levels were 
normalized to β2M levels. Values of 1 indicate no change, <1 indicate a 
decrease, and >1 indicate an increase in Cox- 1 RNA levels due to tigecycline 
treatment. Dotted line indicates an arbitrary cut off at 1.3 times increase 
from control. (B) Expression of Cox- 1 and Cox- 4 proteins was measured by 
immunoblotting and analyzed using densitometry. To calculate a change in 
Cox- 1 levels relative to Cox- 4 levels, the ratio of Cox- 1 to Cox- 4 from day 
11/12 was divided by that from the predose day. Day 11/12 samples were 
not available for some patients, therefore day 10 samples were used for 
patients 18 and 23, and day 8 samples were used for patients 10, 12, 15, 
20, 22, and 26. In addition, predose samples were not available for patients 
7, 11 and 12, therefore, samples from screening day were used. Values of 1 
indicate no change, <1 indicate a decrease, and >1 indicate an increase in 
Cox- 1 levels due to tigecycline treatment. Dotted line indicates an arbitrary 
cut off at 2 times decrease from control.
3038 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
G. A. Reed et al.Tigecycline in Acute Myeloid Leukemia
escalating doses of tigecycline in patients with relapsed 
and refractory AML. However, none of the patients had 
a clinical response, and the study was stopped after admin-
istering tigecycline to 27 patients for 42 cycles over seven 
doses.
In our study, the maximal evaluated dose was 350 mg/
day and the maximal tolerated dose was 300 mg/day. 
Dose- limiting toxicity was observed at 350 mg/day in two 
patients with adverse events including elevated aspartate 
aminotransferase and heart failure in one patient, and 
elevated serum amylase and lipase in the second patient. 
Increases in transaminases and pancreatic enzymes, and 
congestive heart failure have been reported in patients 
treated with tigecycline and are listed as rare drug reac-
tions in the tigecycline package insert [22, 23]. In addition, 
nausea and vomiting are the most frequently reported 
adverse events for the use of tigecycline [17]. In this 
study, grade- 2 nausea, diarrhea and vomiting were reported 
in a total of five patients and judged to be possibly related 
to the treatment.
In our study, tigecycline had a t1/2 of about 9.5 h which 
is 3–4.5- fold lower than previously reported t1/2 values 
[17, 20, 24, 25]. Tigecycline is not extensively metabolized 
and is primarily cleared through biliary excretion (59%) 
and renal elimination (32%) [26, 27]. The tigecycline Cmax 
values obtained following 300 mg/day were 12 μmol/L, 
which is sufficient concentration to reduce the viability 
of AML cell lines and primary leukemic patient samples 
[2, 16]. However, at serum concentrations higher than 
~2 μmol/L tigecycline, the protein binding for tigecycline 
can exceed 87% [25]. Therefore, this is a possible expla-
nation for not observing pharmacodynamics or clinical 
changes despite achieving concentrations that induced cell 
death in culture. In addition, the measured predose con-
centrations on days 2–12 of cycle 1 indicate that the 
steady- state levels of tigecycline were ~1 μmol/L at the 
300 mg/day dose, a concentration at which we did not 
observe any in vitro antileukemic activity [2, 16]. If intra-
cellular and particularly intramitochondrial tigecycline 
concentrations follow the plasma concentration time 
course, then it is likely that there will be significant inter-
vals between infusions when the concentration of the drug 
is below its effective range.
Our Cmax values are from 1.5 to 4 times higher than 
previously reported values at the same doses, and all AUC 
calculated values were approximately twofold higher than 
the reported values [17]. Repeat analysis of plasma aliquots 
from several patients resulted in approximately the same 
concentrations. Moreover, our calibration standards and 
quality control samples consistently fell within range, sup-
porting the validity of our measurements. Two possible 
explanations are proposed for this quantitative difference 
between our data and those reported by Muralidharan 
et al. [17]. The first is based on the analytical technique: 
the improved sensitivity and specificity of the current 
UPLC- MS/MS analytical method relative to those obtained 
with a typical HPLC- UV- based method may provide a 
more accurate measurement of true tigecycline concentra-
tions. The second possible explanation is biological: the 
pharmacokinetics of tigecycline in these cancer patients 
may be quantitatively different than the pharmacokinetics 
of the drug in the healthy subjects recruited for the pub-
lished study.
We have previously shown that tigecycline inhibits 
mitochondrial protein translation in AML cells. Therefore, 
we conducted pharmacodynamic analyses during this study 
to evaluate the effects of tigecycline on the mitochondrial 
protein translation by measuring the levels of mitochon-
drially translated protein, Cox- 1, and comparing it to the 
nuclear translated protein, Cox- 4. No significant pharma-
codynamic responses were observed, consistent with the 
lack of clinical response. Potentially, greater target inhibi-
tion might have been noted if a steady- state concentration 
of greater than 1 μmol/L of tigecycline could have been 
achieved.
As an antimicrobial, tigecycline reversibly binds to the 
30S subunit of the bacterial ribosome, blocking the 
aminoacyl- tRNA from entering the A site, thereby inhibit-
ing elongation of the peptide chain and protein synthesis 
in bacteria [13, 15]. Therefore, it is expected that tige-
cycline also binds to the mitochondrial ribosomes as a 
reversible inhibitor. One reason for the lack of response 
in this trial was that the drug was not on- target for a 
sufficient time to inhibit mitochondrial protein 
translation.
A continuous intravenous infusion of tigecycline could 
be explored as a strategy in future studies to achieve a 
higher steady state concentration. However, the approved 
formulation of tigecycline is relatively unstable after recon-
stitution, making continuous infusion of the drug chal-
lenging for ambulatory patients. To increase the stability 
of tigecycline after reconstitution and permit the evaluation 
of continuous infusions of the drug, we have identified 
a new formulation of tigecycline containing ascorbic acid 
and vitamin E that maintains the stability of tigecycline 
for at least 7 days [16].
Antibiotics that inhibit bacterial protein synthesis have 
been reported to cross- react with human mitochondrial 
ribosomes and inhibit mitochondrial protein synthesis 
[28]. For example, chloramphenicol can cause bone mar-
row suppression, which has been attributed to inhibition 
of mitochondrial protein synthesis by binding the A- site 
of the mitochondrial ribosome [28]. Oxazolidinones also 
can cause myelosuppression and inhibit human mitochon-
drial ribosomes [29, 30]. Thus, while structurally distinct 
from bacterial and cytosolic ribosomes, antimicrobials that 
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inhibit bacterial ribosomes have a tendency to cross react 
with mitochondrial ribosomes. However, linezolid and 
chloramphenicol are less potent inhibitors of mitochondrial 
protein synthesis than tigecycline, so they would likely 
be less effective as therapeutic agents for leukemia.
In conclusion, this study represents the first clinical 
evaluation of tigecycline as a single agent in relapsed 
and refractory AML patients. The maximal evaluated dose 
was 350 mg/day and the maximal tolerated dose was 
300 mg/day. Dose- limiting toxicity was observed at the 
highest dose level, but tigecycline showed a favorable 
safety profile at doses 300 mg/day and under. 
Pharmacokinetic studies indicate that daily one- hour infu-
sions of tigecycline did not achieve and maintain effective 
steady- state levels due to a short t1/2. Consistent with 
this finding, no clinical or pharmacodynamic responses 
were seen. Future studies should utilize the more stable 
formulation of tigecycline to permit continuous infusion 
to increase the concentration of tigecycline in the leu-
kemic cells. Potentially through this approach, greater 
biological and clinical efficacy of tigecycline could be 
observed in patients with AML.
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